UNSPSC 51263146: Arotinolol hydrochloride

This classification denotes a beta-adrenergic blocking agent with the molecular formula C15H21N3O2S3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9DOI1HT306, chemically known as 2-thiophenecarboxamide, 5-(2-((3-((1,1-dimethylethyl)amino)-2-hydroxypropyl)thio)-4-thiazolyl)-, monohydrochloride, (+-)- but more generally known as arotinolol hydrochloride, which bears US NIH Compound Identifier 155032.

European Medicines Agency schedules Arotinolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00590MIG. Most nations, for tariff and trade purposes, schedule arotinolol hydrochloride under HS 29341000 and SITC 51579. As of Q4 2014, AROTINOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)(C)NCC(CSC1NC(CS1)C2CCC(S2)C(=O)N)O.CL.

UNSPSC 51263146 Arotinolol hydrochloride is a Commodity code representing a specific pharmaceutical product, but recent state and local solicitations show little activity directly aligned with procurement of this individual drug compound. The one recent opportunity explicitly tagged to this code—Seminole County, Florida's IFB60459723LAS for Naloxone and Safe Drug Deactivation Systems—targets naloxone procurement rather than arotinolol, indicating a potential classification mismatch in the source data. State and local governments do purchase pharmaceuticals and medical supplies through formal competitive processes, typically via county health departments, state health agencies, and community health initiatives, but the specific procurement of arotinolol hydrochloride does not appear in the recent opportunities block with meaningful frequency or clarity.

Activity under this Commodity code remains limited based on available recent solicitations. Seminole County, Florida posted IFB60459723LAS on June 30, 2026, with a response deadline of July 26, 2023 (note: date discrepancy in source), to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding for the Seminole County Community Health Building. The Texas Health and Human Services Commission issued an exploratory RFI (HHS0017013) on April 3, 2026, regarding direct-to-manufacturer prescription programs, but this solicitation does not specify arotinolol or related beta-blockers. Given the mismatch between the code's nominal scope and the naloxone focus of the tagged opportunity, firms should verify with issuing bodies whether arotinolol or other specific pharmaceutical compounds are actually being procured under this code before committing business development resources.